Why Wall Street sees a $39,800 pancreatic cancer pill as proof of a much bigger bet
Dr. Danish Nagda, a shareholder in the developer, told Fortune it was "incredibly exciting ... maybe half a decade away from the post-cancer era."
Read the full story at fm-term-meta-233910339-mutual-fund | FORTUNE →